{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:58:43Z","timestamp":1789905523355,"version":"4.0.1"},"reference-count":29,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Cir. Bras."],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1590\/s0102-865020160020000008","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T00:58:22Z","timestamp":1457225902000},"page":"133-137","source":"Crossref","is-referenced-by-count":15,"title":["Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat"],"prefix":"10.1590","volume":"31","author":[{"given":"Siamak","family":"Reyhani-Rad","sequence":"first","affiliation":[{"name":"Islamic Azad University, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Tabriz University of Medical Sciences, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00702-005-0368-3","article-title":"Serotonergic mechanisms in Parkinson`s Disease: opposing results from preclinical and clinical data","volume":"113","author":"Scholtissen B","year":"2006","journal-title":"J Neural Transm"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.20369","article-title":"Blood-brain barrier dysfunction in parkinsonian midbrain in vivo","volume":"57","author":"Kortekaas R","year":"2005","journal-title":"Ann Neurol"},{"issue":"S3","key":"ref3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/ana.10481","article-title":"Neuroinflammatory processes in Parkinson's disease","volume":"53","author":"Hunot S","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte-endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott NJ","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A (2A) receptor antagonists in Parkinson's disease","volume":"105","author":"Xu K","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen JF","year":"2001","journal-title":"J Neurosci"},{"issue":"4","key":"ref7","first-page":"1175","article-title":"Role of 5-Hydroxytryptamine 1A receptors in 6-hydroxydopmaine-induced catalepsy-like immobilization in rats: a therapeutic approach for treating catalepsy of Parkinson's disease","volume":"11","author":"Reyhani-Rad S","year":"2012","journal-title":"IJPR"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1734-1140(10)70264-4","article-title":"Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rat","volume":"62","author":"Nayebi AM","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"2","key":"ref9","first-page":"149","article-title":"Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats","volume":"2","author":"Mahmoudi J","year":"2012","journal-title":"Adv Pharm Bull"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pneurobio.2007.09.002","article-title":"Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ''fine tuning'' modulation","volume":"83","author":"Chen JF","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/mds.21706","article-title":"Coffee and tea consumption and the risk of Parkinson's disease","volume":"22","author":"Hu G","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.ejcn.1602788","article-title":"Prospective study of coffee consumption and risk of Parkinson's disease","volume":"62","author":"Saaksjarvi K","year":"2008","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2003.07.006","article-title":"Dose-dependent protective effect of coffee, tea, and smoking in Parkinson disease: a study in ethnic Chinese","volume":"216","author":"Tan EK","year":"2003","journal-title":"J Neurol Sci"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.10277","article-title":"A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease","volume":"52","author":"Hernan MA","year":"2002","journal-title":"Ann Neurol"},{"issue":"16","key":"ref15","first-page":"2153","article-title":"Caffeine analogs: biomedical impact,cellular and molecular","volume":"64","author":"Daly J W","year":"2007","journal-title":"Life SCI"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1471-4159.2003.02306.x","article-title":"Adenosine A 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors","volume":"89","author":"Pintor A","year":"2004","journal-title":"J Neurochem"},{"issue":"34","key":"ref17","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","article-title":"Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively","volume":"23","author":"Alfinito PD","year":"2003","journal-title":"J Neurosci"},{"key":"ref18","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos G","year":"1982"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019983","article-title":"The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo","volume":"6","author":"Lammer A B","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober A","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease","volume":"105","author":"Xu K","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","article-title":"Adenosine A2A receptor antagonists for Parkinson's disease","volume":"22","author":"Hauser RA","year":"2005","journal-title":"Drugs Aging"},{"issue":"26","key":"ref23","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.lfs.2005.04.029","article-title":"New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists","volume":"77","author":"Pinna A","year":"2005","journal-title":"Life Sci"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1523\/JNEUROSCI.3008-05.2006","article-title":"Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"26","author":"Xu K","year":"2006","journal-title":"J Neurosci"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14728222.4.5.635","article-title":"Adenosine receptors in neurological disorders","volume":"4","author":"Impagnatiello F","year":"2000","journal-title":"Emerg Ther Targets"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF03033210","article-title":"Adenosine A2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease","volume":"3","author":"Morelli M","year":"2001","journal-title":"Neurotoxicity Res"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/syn.1070","article-title":"SCH 58261, an A2A adenosine receptor antagonist, counteracts the parkinsonian-like muscle rigidity in rats","volume":"41","author":"Wardas J","year":"2001","journal-title":"Synapse"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neuroscience.2010.02.020","article-title":"Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease","volume":"167","author":"Xu K","year":"2010","journal-title":"Neurosciences"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0893-133X(99)00144-X","article-title":"Effects of SCH 58261, an Adenosine A2A receptor antagonist, on quinpirole-induced turning in 6-Hydroxydopamine-lesioned rats: lack of tolerance after chronic caffeine intake","volume":"22","author":"Popoli P","year":"2000","journal-title":"Neuropsychopharmacology"}],"container-title":["Acta Cirurgica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/acb\/v31n2\/0102-8650-acb-31-02-00133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:02:42Z","timestamp":1567670562000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-86502016000200133&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0102-86502016000200133"],"URL":"https:\/\/doi.org\/10.1590\/s0102-865020160020000008","relation":{},"ISSN":["0102-8650"],"issn-type":[{"value":"0102-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}